Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer

StatusCompleted
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: St. Jude Children's Research Hospital to St. Jude Children's Research Hospital Show 4 more changesShow less
    • Trial completed
    • Study completion date changed from estimate of Aug 2026 to Jul 9, 2026
    • Eligibility criteria expanded, about 16 words
    • Site details revised
  2. 2 versions Re-verified since Feb 3, 2026, no change to tracked fieldsv15-v16
  3. Enrollment target: estimated 50 to confirmed 44v14
  4. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v13
  5. Primary completion date changed from estimate of Jun 2025 to Jun 6, 2025v12
Show 10 earlier versionsHide 10 earlier versions
  1. Primary completion date: Dec 2024 to Jun 2025
    • Study completion date: Aug 2025 to Aug 2026
    v11
  2. Enrollment target: 30 to 50v10
  3. Primary completion date: Jun 2024 to Dec 2024
    • Study completion date: Feb 2025 to Aug 2025
    v9
  4. 2 versions Re-verified since Jul 26, 2023, no change to tracked fieldsv7-v8
  5. Primary completion date: Dec 2023 to Jun 2024
    • Study completion date: Jun 2024 to Feb 2025
    • Eligibility criteria expanded, about 12 words
    v6
  6. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 2023 to Jan 5, 2023
    • Site details revised
    v5
  7. Start date: Nov 2022 to Jan 2023v4
  8. Trial status: Recruiting to Not Yet Recruiting
    • Site details revised
    v3
  9. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Oct 2022 to Nov 2022
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Survivors of childhood cancer are at greater risk for long-term cognitive impairments that include attention, executive function, intelligence, memory, and processing speed. The participants are a survivor of acute lymphoblastic leukemia (ALL) or Hodgkin's lymphoma (HL). Because of your treatment the participant may have developed trouble with thinking and learning. Primary Objective To evaluate the feasibility of using home-based tPBM paired with remote cognitive training to improve cognitive performance in survivors of ALL and HL. Secondary Objectives To estimate the potential efficacy of alpha and gamma frequency tPBM on cognitive performance in survivors of ALL and HL. Exploratory Objectives To estimate the effects of home-based tPBM paired with remote cognitive training on patient reported symptoms of executive dysfunction, sleep, depression, anxiety, fatigue, and pain in survivors of ALL and HL.
Trial Details
NCT Number NCT05550948
Lead Sponsor St. Jude Children's Research Hospital
Conditions
(from sponsor)		 ALL, Hodgkin Lymphoma, Cancer, Survivorship
Related terms Hodgkin Disease, Neoplasms
Enrollment 44 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov